U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07321834) titled 'A Study to Evaluate AI-09 In Participants With Glabellar Lines' on Jan. 02.
Brief Summary: Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
Study Start Date: Dec. 03, 2025
Study Type: INTERVENTIONAL
Condition:
Glabellar Lines
Intervention:
BIOLOGICAL: AI-09 Ready Use Injectable Botulinum Toxin
AI-09 Ready Use Injectable Botulinum Toxin
BIOLOGICAL: Vehicle
Vehicle
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Eirion Therapeutics Inc.
Disclaimer: Curated by HT Syndication....